Igor Puzanov on Monitoring Cardiologic Toxicities from Checkpoint Inhibitors

Video

Igor Puzanov discusses the rare cardiologic adverse events that can occur when a patient is on checkpoint inhibitors.

Igor Puzanov, MD, MSCI, FACP, director of the Early Phase Clinical Trials Program, chief of Melanoma, and co-leader of the CCSG Experimental Therapeutics Program at Roswell Park Cancer Institute, discusses the ways to monitor patients for potential cardiologic adverse events from checkpoint inhibitors.

A recent case study conducted by Puzanov examined two patients who experienced inflammation of the heart muscles while on the doublet treatment of ipilimumab-nivolumab. The inflammation was unable to be reversed by steroids and the patients eventually died from heart failure.

While this is a rare side effect, Puzanov states it is important to monitor patients on this doublet closely. Patients should come in for weekly check-ins — as the inflammation in the two patients began at about two weeks, before the second dose – and have their CPK and troponin levels checked. Additionally, if there is any question about the patient’s status, an EKG can be done. Early intervention is key, with steroids or immunosuppressants.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
Photo of a woman with brown hair and a floral blouse
Photo of a woman with a blue border around the image
2 experts are featured in this series.
2 experts are featured in this series.
Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
Image of a woman with white hair in front of an Oncology Nursing News blue background
2 experts are featured in this series.
Image of a man in a suit standing in front of a blue Oncology Nursing News backdrop